EAPH (Easton Pharmaceuticals) Current Deferred Revenue: $0.00 Mil (As of Sep. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EAPH Easton Pharmaceuticals Inc EAPH
12 GF Score
Price $0.00
View Full Analysis

What is Easton Pharmaceuticals Current Deferred Revenue?

Easton Pharmaceuticals EAPH -95.00% 12 Current Deferred Revenue is $0.00 Mil as of Sep. 2021. GuruFocus rates EAPH with a GF Score™ of 12/100.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Easton Pharmaceuticals's current deferred revenue for the quarter that ended in Sep. 2021 was $0.00 Mil.

Easton Pharmaceuticals Current Deferred Revenue Related Terms

Easton Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Easton Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easton Pharmaceuticals Current Deferred Revenue Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.13 0.00 0.00 0.00

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EAPH
12GF Score
Easton Pharmaceuticals Inc EAPH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Easton Pharmaceuticals (EAPH) has a Current Deferred Revenue of $0.00 Mil as of Sep. 2021. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Easton Pharmaceuticals and its competitors.
Is Easton Pharmaceuticals' Current Deferred Revenue too high?
Easton Pharmaceuticals' current Current Deferred Revenue is $0.00 Mil. Overall, Easton Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Easton Pharmaceuticals' Current Deferred Revenue compare to FPSUF and GCAN?
Easton Pharmaceuticals' Current Deferred Revenue of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Easton Pharmaceuticals and its competitors. Easton Pharmaceuticals's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easton Pharmaceuticals stock overvalued right now?
Easton Pharmaceuticals (EAPH) has a current Current Deferred Revenue of $0.00 Mil. The current Current Deferred Revenue is $0.00 Mil. Easton Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Easton Pharmaceuticals (EAPH), the current Current Deferred Revenue is $0.00 Mil as of Sep. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Easton Pharmaceuticals Business Description

Address 2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.
12GF Score

Get the complete analysis for EAPH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price